Forecast

There is no analyst data available for this company.

News Go to news feed

IGC Pharma reports strategic growth and progress in Alzheimer's research in Q2 2025

IGC Pharma reported revenue of $310,000 and a projected loss per share of -$0.02 in the second quarter of 2025, with a focus on strategic development in Alzheimer's research and operational efficiency. The company expanded its clinical trial sites and plans to launch a new diagnostic platform, but remains unprofitable for now due to its long-term research focus. CEO Ram Cunda emphasized the company's innovation and its goal to address Alzheimer's with new therapeutic approaches. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2023, IGC RESOURCES INC. has already paid €1.93 in dividends. The last payout was in July 2023.

Financials

In the last quarter, IGC RESOURCES INC. had revenue of €21.96M and net profit of €2.58M

(EUR)	Jun 2026	YoY
Revenue	21.96M	18.03%
Gross profit	7.97M	4.47%
Net profit	2.58M	151.21%
EBITDA	2.12M	14.22%

Fundamentals

Metric	Value
Market capitalization	€42.64M
Number of shares	576.9M
52-week high/low	€0.0941 - €0.0526
Dividends	No
Beta	0.45
P/E ratio	-100.00
PEG ratio	-0.39
P/B ratio	1.07
P/S ratio	0.54

Company profile

Decibel Cannabis Company Inc. beschäftigt sich mit dem Anbau, der Verarbeitung, der Produktion und dem Einzelhandelsverkauf von Cannabisprodukten in Kanada. Das Unternehmen bietet Cannabisblüten, Cannabis-Pre-Rolls und Cannabis-Biomasse für lizenzierte Produzenten in Kanada an. Das Unternehmen befasst sich auch mit der Extraktion, Verarbeitung und Herstellung verschiedener Cannabisprodukte, einschließlich Vape-Kartuschen, Cannabis-Infusionsprodukten und Cannabisextrakten. Es bietet seine Produkte unter den Marken Qwest, Qwest Reserve, Blendcraft by Qwest und General Admission an. Decibel Cannabis Company Inc. hat seinen Hauptsitz in Calgary, Kanada.